about
Targeting DNA Replication Stress for Cancer TherapyRadioresistance of Brain TumorsDevelopment of cell-cycle checkpoint therapy for solid tumorsDNA damage response and prostate cancer: defects, regulation and therapeutic implicationsEmerging Treatment Paradigms in Radiation OncologyA haploid genetic screen identifies the G1/S regulatory machinery as a determinant of Wee1 inhibitor sensitivity.Cell cycle checkpoint in cancer: a therapeutically targetable double-edged swordTargeting lung cancer through inhibition of checkpoint kinases.A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.Targeting cell cycle regulators in hematologic malignancies.Cell cycle control, DNA damage repair, and apoptosis-related pathways control pre-ameloblasts differentiation during tooth development.DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis.The Fcp1-Wee1-Cdk1 axis affects spindle assembly checkpoint robustness and sensitivity to antimicrotubule cancer drugs.Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress."Ready, set, go": checkpoint regulation by Cdk1 inhibitory phosphorylation.Herpesvirus saimiri MicroRNAs Preferentially Target Host Cell Cycle Regulators.Structural prediction of the interaction of the tumor suppressor p27KIP1 with cyclin A/CDK2 identifies a novel catalytically relevant determinantSensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination RepairTargeting protein kinases to reverse multidrug resistance in sarcoma.Chemogenetic profiling identifies RAD17 as synthetically lethal with checkpoint kinase inhibition.Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer.Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitorsDrugging ATR: progress in the development of specific inhibitors for the treatment of cancer.Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma.Cytokinetic effects of Wee1 disruption in pancreatic cancer.The cell cycle checkpoint inhibitors in the treatment of leukemias.HPLC-UV method for simultaneous determination of MK-1775 and AZD-7762 in both acetonitrile-aqueous solution and mouse plasma.Targeting protein kinase-b3 (akt3) signaling in melanoma.Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity.WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability.Pyrimidine-based tricyclic molecules as potent and orally efficacious inhibitors of wee1 kinase.Consequences of abnormal CDK activity in S phase.MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.miR-15b modulates multidrug resistance in human osteosarcoma in vitro and in vivoMutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer.QuaDMutEx: quadratic driver mutation explorerGSK3 inhibitors stabilize Wee1 and reduce cerebellar granule cell progenitor proliferation.Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases.
P2860
Q26739923-A30E96EC-4124-4196-8B8C-71AA47B5592AQ26752579-BB037B7F-3621-4A5F-97AC-872B0344C562Q26781187-5E1D0037-8DF6-44F1-BACC-F3AC35CC6C85Q26829155-328B6679-4E74-41B0-B4F5-4A1FC742551BQ26853461-E92D0097-5B26-4AAC-BEA0-991DE65545F9Q27323300-07EC8B09-D559-42B8-93DB-63F9FBBE94FFQ28078268-E8C6F0DA-B669-4978-A099-7F5194D3C9B3Q35128547-D006AB6B-CF1E-49D1-BF31-063F252ED751Q35287823-49D66044-6359-43FE-98BF-B0991669324AQ35334436-F3F87A79-BB14-45A4-AEE8-B1442563E4E1Q35743285-4C8E080C-C04E-4180-99D0-2CD9A151DEADQ35941085-D16A2662-EC38-4150-AD95-24E1571D5DD3Q35941489-ED9207FB-0F3D-4A96-878A-12D035190676Q35955216-D4D7B973-F95C-471C-B67F-3CD839B16B51Q36124627-3761ED36-E430-48B9-903A-F99B1CD94C2CQ36208124-E7F83486-D3DB-4DAA-AD27-88E3AD90226DQ36240680-82CE24AC-D95D-4BA4-983F-373657920D3AQ36309585-1E0E8F68-2052-46AE-A7CA-0810FBCA0372Q36527950-DF86A181-9720-4965-B5B5-F1AB90400941Q36546455-C36757AA-3453-42D8-B901-0150E347B498Q37017110-4A7FDEB5-C628-422C-AF23-FB583FE5ED13Q37580332-4919DDC4-193E-4E0B-977F-F7EEB1908D52Q37634102-35010C71-AD5D-4ED5-97F6-92608928A45FQ38261022-5611BD45-829C-42C1-B64B-49AA181E93A4Q38523589-58843EF9-BBDD-44B5-B3FE-FDC73A7639B1Q38763225-FC457940-9595-4969-AED8-6E5033222DCEQ38793178-FFA98621-CA6C-4982-85E4-448CD7316629Q38868502-34C4F7E0-172D-409F-9B3C-D85A04A52E76Q39020753-FCAD1244-34E5-4696-8C34-2F442F41AE99Q39074281-2858B3AE-1B31-4842-A62D-97F613CD9583Q40180908-DA57209C-4837-4584-94E7-CFE948B58B53Q41618744-55148F8B-BFC8-48BE-90A5-B4C69F38C69CQ41887994-FA594659-E819-47C7-9139-29AC3E79F139Q41905265-3B663E1E-08DE-43FE-A58F-B3BFF199BE51Q42317541-3F9BD079-7E90-42B1-B41A-B75963BB0EAEQ42322707-D31460DF-602A-454E-B5B6-373C233E43BBQ42366556-E4685C4A-BEE6-4569-810A-BE60F12C7BFFQ42634268-D49199C5-057D-439C-B30D-F8F0020AB1EAQ43180207-B49C94E3-827A-47B7-82CA-AF6214925280Q46063736-9FFDDDF5-6C19-4148-852B-09306A433B2B
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Wee1 kinase as a target for cancer therapy.
@en
Wee1 kinase as a target for cancer therapy.
@nl
type
label
Wee1 kinase as a target for cancer therapy.
@en
Wee1 kinase as a target for cancer therapy.
@nl
prefLabel
Wee1 kinase as a target for cancer therapy.
@en
Wee1 kinase as a target for cancer therapy.
@nl
P2093
P2860
P356
P1433
P1476
Wee1 kinase as a target for cancer therapy.
@en
P2093
James H Doroshow
Shivaani Kummar
P2860
P304
P356
10.4161/CC.26062
P577
2013-08-26T00:00:00Z